Status:
COMPLETED
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Vaginal Atrophy
Eligibility:
FEMALE
40-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether Bazedoxifine/conjugated estrogens are effective in the treatment of vaginal atrophy.
Eligibility Criteria
Inclusion
- Generally healthy, postmenopausal women, aged 40 to 65 years
- Intact uterus
- At least 1 moderate to severe vulvar/vaginal symptom that is most bothersome
Exclusion
- Hypersensitivity to estrogens, endometrial hyperplasia, known or suspected estrogen-dependent neoplasia
- Thrombophlebitis, thrombosis or thromboembolic disorders
- Neuro-ocular disease
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT00238732
Start Date
October 1 2005
End Date
March 1 2007
Last Update
December 28 2007
Active Locations (63)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
Montgomery, Alabama, United States
3
Scottsdale, Arizona, United States
4
Tucson, Arizona, United States